Belay Diagnostics Validates Vantage™ Assay for CNS Cancer Detection and Prognosis Belay Diagnostics has announced the successful validation of its Vantage™ assay for detecting MGMT promoter methylation in cerebrospinal fluid, significantly enhancing CNS cancer diagnosis.

Belay Diagnostics Validates Vantage™ Assay for CNS Cancer Detection and Prognosis #United_States #Chicago #Belay_Diagnostics #CNS_Cancer #Vantage_Assay